Enzalutamide and Prostvac for patients with PSA only disease after primary treatment

This very significant development could become the standard treatment for prostate cancer in the future.


Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer. NIH Study- Recruiting- ClinicalTrials.gov  Identifier: NCT01875250

This entry was posted in Immune Therapy, Prostate Cancer, PSA, Radiation Therapy, Radical Prostatectomy. Bookmark the permalink.